Table 3.

Complications of antenatal treatment

ReferenceAEs in FBS/IUPT n/N (%)*Complications after FBS or IUPT (n)SEs in IVIG n/N (%)*Reported SEs in IVIG treatment (n)SEs in steroids n/N (%)*Reported SEs in steroid treatment (n)
241/9 (11)Emergency CS due to fetal distress (1); <34 wk (0)NRNRNRNR
194/37 (11)Emergency CS or delivery (4); <34 wk (NR); due to fetal distress (3); insertion bleeding (1)NRNRNRNR
343/99 (3)Perinatal death (1); emergency CS due to fetal distress (3); <34 wk (0)NRNRNANA
374/74 (5)Emergency CS (4); <34 wk (3); due to fetal distress (2); PROM (2)NRRash (1) discontinued IVIG, headache, fatigueNRGestational diabetes (7), insomnia, mood swings
3511/79 (14)Fetal death (1); neonatal death (1); emergency CS or delivery (10); <34 wk (NR); due to fetal distress (8); streaming (1); PROM (1)NRNRNRNR
182/40 (5)Neonatal death after fetal distress (1); emergency CS due to exsanguination (1)NRNRNRNR
2815/38 (39)Fetal death (2); after exsanguination (1); emergency CS/delivery (13); <34 wk (6); due to fetal distress (6), infection (1), technical difficulties (3), cord spasm or thrombosis (2), placental artery bleeding (1)1/18 (6)Headache and tachycardia (1), continued IVIGNRNR
232/10 (20)Emergency CS due to insertion bleeding (2), <34 wk (1)NRNRNANA
424/15 (27)Emergency CS or delivery (4); <34 wk (1); due to fetal distress (3); acute amnionitis after ROM (1)1/11 (9)Headache and tachycardia (1), continued IVIGNRNR
205/59 (9)Fetal or neonatal death after exsanguination (5)0/54None2/26 (8)Oligohydramnios (2) dexamethasone 1.5 mg - dexamethasone 4.5 mg
332/10 (20)Pregnancy loss at 16 wk’s gestation (1); neonatal death due to chorioamnionitis at 25 wk (1);0/10NoneNANA
401/15 (7)fetal death due to cord hematoma (1)NRNRNRNR
22NRNRNRNR5/9 (56)Oligohydramnios (4) dexamethasone 5 mg
  • AE, adverse event; CS, cesarean section; CTG, cardiotocogram; NR, not reported; PROM, prelabor rupture of membranes; SE, side effect.

  • * Number of reported complications (n) versus the total number of patients treated with this specific strategy (N).

  • Number of side effects reported; the total number of patients that reported a side effect is unclear.

  • The complications occurring during this study were reported in detail elsewhere.40